| Literature DB >> 29855842 |
K Bolhuis1, L J Bakker2, J T Keijer3, P J de Vries4.
Abstract
Staphylococcus aureus bacteraemia (SAB) is associated with high-mortality and complication rates. A multidisciplinary approach is needed to predict, detect and treat complications. In this pre- and post-intervention study, we investigated the effects of a hospital-wide protocol for diagnosis, classification and treatment of SAB. It was hypothesized that complications and endocarditis would be better identified and treated. Medical records of SAB patients admitted in 2011 and 2012 (pre) were analysed. In 2013, a protocol, describing risk factors, diagnostic classification and recommended treatment, was implemented. In 2014 and 2015 (post), SAB patients were followed prospectively. Transthoracic (TTE) or transoesophageal cardiac ultrasound (TEE) was chosen following a decision tree. A resident internal medicine acted as contact person. Pre-intervention, 98 patients were eligible for analysis compared to 85 patients post-intervention. Age and number of risk factors were slightly higher post-intervention; other baseline characteristics were similar. Most SAB-patients were classified as complicated (89 and 82% pre- and post-intervention, respectively). Follow-up blood cultures drawn within 2 days after initiating treatment increased from 51 to 85%. Cardiac ultrasounds increased from 44 to 83% for TTE and 13 to 24% for TEE. Endocarditis was more frequently diagnosed (4 vs. 12%). Additionally, duration of antibiotic therapy increased. The 3-month mortality did not change significantly (33% pre-intervention vs. 35% post-intervention; p > 0.05). Introduction of a hospital-wide protocol for SAB management increased standard of care, created awareness among clinicians to properly classify SAB, search for endocarditis and adapt duration of antibiotic treatment. Mortality did not decrease.Entities:
Keywords: Bacteraemia; Echocardiography; Infective endocarditis; Staphylococcus aureus; Treatment
Mesh:
Year: 2018 PMID: 29855842 PMCID: PMC6061069 DOI: 10.1007/s10096-018-3284-9
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Fig. 1Protocol for diagnosis, classification and treatment of SAB. SAB, Staphylococcus aureus bacteraemia; TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography
Fig. 2Flow diagram of events included in the study. SAB, Staphylococcus aureus bacteraemia
Patient demographic characteristics. Staphylococcus aureus bacteraemia before (2011–2012) and after a protocol adherence intervention (2014–2015)
| Variable | Pre-intervention ( | Post-intervention group ( | |
|---|---|---|---|
| Age, median years (min, max) | 69, 65 (19, 94) | 76.49 (35, 98) |
|
| Female sex | 47 (48%) | 35 (41%) |
|
| Classification SAB | |||
| Uncomplicated SAB | 11 (11%) | 15 (18%) |
|
| Complicated SAB | 87 (89%) | 70 (82%) | |
| Risk factors | |||
| Community acquisition | 63 (64%) | 55 (65%) | |
| Diabetes mellitus | 28 (29%) | 26 (31%) | |
| Positive follow-up blood cultures 48/72 h | 13 (13%) | 21 (25%) | |
| Prosthetic material | 31 (32%) | 29 (34%) | |
| Persistent fever after 72 h | 4 (4%) | 9 (11%) | |
| Catheter-related and in situ | 3 (3%) | 2 (2%) | |
| Immunocompromised | 12 (12%) | 9 (11%) | |
| Metastatic infections | 23 (23%) | 23 (27%) | |
| Purulent thrombophlebitis | 11 (11%) | 0 (0%) | |
| Malignancy | 18 (18%) | 10 (12%) | |
| Alcohol | 10 (10%) | 7 (8%) | |
| Haemodialysis | 3 (3%) | 1 (1%) | |
| No. of risk factors | |||
| 0 | 11 (11%) | 15 (18%) |
|
| 1 | 27 (28%) | 16 (19%) | |
| 2 | 31 (32%) | 28 (33%) | |
| 3 | 22 (22%) | 16 (19%) | |
| 4 | 5 (5%) | 6 (7%) | |
| 5 | 3 (3%) | 4 (5%) | |
| Source of infection | |||
| Health care-related | 50 (51%) | 37 (44%) | |
| Surgery | 11 (22%) | 6 (16%) | |
| Urinary tract/CAD | 6 (12%) | 8 (22%) | |
| CVC/PAC | 11 (22%) | 5 (14%) | |
| Peripheral catheter | 12 (24%) | 11 (30%) | |
| Unknown source | 26 (52%) | 21 (57%) | |
Patient demographics. SAB, Staphylococcus aureus bacteraemia; CAD, urine catheter; CVC, central venous catheter; PAC, port a cath; NS, not significant. A p value < 0.05 is considered statistically significant
Quality of care indicators
| Diagnostic and therapeutic management of | |||
|---|---|---|---|
| Variable | Pre-intervention ( | Post-intervention | |
| Diagnostic workup | |||
| Echocardiography performed in complicated SAB patients | |||
| TTE | 38 (44%) | 58 (83%) |
|
| TEE | 11 (13%) | 17 (24%) |
|
| 2nd blood cultures obtained after 48–72 h | 50 (51%) | 72 (85%) |
|
| Adequate antibiotic therapy | |||
| Yes | 38 (39%) | 60 (71%) |
|
| No | 59 (58%) | 24 (28%) | |
| Not started | 4 | 0 | |
| Inadequate length | 53 | 24 | |
| Inadequate dose | 3 | 0 | |
| Unknown | 1 (1%) | 1 (1%) | |
| Intravenous antibiotic treatment | |||
| < 14 days | 32 (33%) | 8 (9%) | |
| ≥ 14 days | 44 (45%) | 58 (68%) | |
| Lost to FU < 14 days | 18 (18%) | 19 (22%) | |
| Death/withdrawing therapy | 15 | 16 | |
| Transfer | 2 | 2 | |
| Unknown | 1 | 1 | |
| Adequate AB not started | 4 (4%) | 0 (0%) | |
| Antibiotics stopped due to death or withdrawing therapy | |||
| Adequate AB not started | 4 | 0 | |
| Yes | 23 | 21 | |
| No | 65 | 57 | |
| Transfer | 5 | 5 | |
| Unknown | 1 | 2 | |
| Treatment duration (mean)a | 17.3 ( | 23.0 ( |
|
| Uncomplicated SAB (mean/days) | 10.3 ( | 13.8 ( | |
| Complicated SAB (days, mean) | 18.2 ( | 26.3 ( | |
| Length of hospital stayc (mean, days) | 27.5 | 22.4 | NS |
SAB, Staphylococcus aureus bacteraemia; TTE, transthoracic echocardiography; TEE, transoesophageal echocardiography; FU, follow-up; AB antibiotic treatment; NS, not significant. A p value < 0.05 is considered statistically significant.
aMean treatment duration. Patients were excluded when adequate antibiotics were not started or if antibiotic therapy was stopped due to death, withdrawing therapy or transfer to a different health care clinic
bEchocardiography in complicated SAB patients
cLength of hospital stay was calculated from date positive blood culture was taken till day of discharge. Patients transferred to different hospital were excluded
Secondary outcomes
| Variable | Pre-intervention ( | Post-intervention group ( |
|---|---|---|
| Infectious complications | 38 (39%) | 38 (45%) |
| Endocarditis | 4 (4%) | 10 (12%) |
| Spondylodiscitis | 8 (8%) | 5 (6%) |
| Abscesses | 10 (10%) | 13 (15%) |
| Septic arthritis | 3 (3%) | 6 (7%) |
| Prosthetic joint infection | 5 (5%) | 7 (8%) |
| Endovascular infection | 2 (2%) | 2 (2%) |
| Relapse within 3 months | 5 (5%) | 2 (2%) |
| Cerebral septic embolism | 4 (4%) | 4 (5%) |
| Mortality | ||
| 30-day mortality | 25 (26%) | 22 (26%) |
| Uncomplicated | 3 | 1 |
| Complicated | 22 | 21 |
| Unknown/lost to FU | 2 | 1 |
| 90-day mortality | 32 (33%) | 30 (35%) |
| Uncomplicated | 4 | 3 |
| Complicated | 28 | 27 |
| Unknown/lost to FU | 3 | 1 |
Secondary outcome: complications. FU, follow-up